Back to Feed
ClinicalTrials.gov|Clinical Trial
Horizon Two Adaptive Platform Study in High Risk Newly Diagnosed Multiple Myeloma
Multiple Myeloma Research Consortium
Abstract
The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigational therapies in high-risk newly diagnosed multiple myeloma patients using an integrated and patient-centric clinical research platform that enables longitudinal learning and sharing of knowledge and investigates multiple novel therapeutic strategies within one trial platform. Phase: PHASE2 Status: RECRUITING Conditions: High Risk Newly Diagnosed Multiple Myeloma Interventions: Bispecific Monoclonal Antibody and Triplet Therapy; Monoclonal Antibody with Stem Cell Transplant
Keywords
High Risk Newly Diagnosed Multiple Myeloma